Your browser is no longer supported. Please, upgrade your browser.
OPTN OptiNose, Inc. daily Stock Chart
OPTN [NASD]
OptiNose, Inc.
Index- P/E- EPS (ttm)-2.46 Insider Own0.40% Shs Outstand45.91M Perf Week-1.01%
Market Cap201.18M Forward P/E- EPS next Y-1.38 Insider Trans-2.60% Shs Float33.31M Perf Month-8.80%
Income-108.50M PEG- EPS next Q-0.54 Inst Own87.20% Short Float20.81% Perf Quarter-29.52%
Sales40.80M P/S4.93 EPS this Y2.00% Inst Trans0.41% Short Ratio15.30 Perf Half Y6.20%
Book/sh0.27 P/B14.59 EPS next Y37.00% ROA-66.90% Target Price- Perf Year-47.18%
Cash/sh2.45 P/C1.61 EPS next 5Y74.40% ROE-282.10% 52W Range3.28 - 11.66 Perf YTD-57.27%
Dividend- P/FCF- EPS past 5Y- ROI-75.50% 52W High-66.21% Beta-
Dividend %- Quick Ratio4.10 Sales past 5Y- Gross Margin84.00% 52W Low20.12% ATR0.21
Employees102 Current Ratio4.30 Sales Q/Q53.70% Oper. Margin- RSI (14)40.93 Volatility4.83% 5.72%
OptionableNo Debt/Eq8.33 EPS Q/Q15.00% Profit Margin- Rel Volume0.26 Prev Close3.95
ShortableYes LT Debt/Eq8.33 EarningsAug 04 BMO Payout- Avg Volume452.95K Price3.94
Recom1.80 SMA200.50% SMA50-13.17% SMA200-26.36% Volume117,361 Change-0.25%
Dec-18-19Initiated Cowen Outperform $25
Aug-08-18Initiated Cantor Fitzgerald Overweight
Sep-29-20 09:30AM  
Sep-14-20 08:00AM  
Aug-14-20 01:11PM  
08:37AM  
08:04AM  
Aug-13-20 04:26PM  
Aug-11-20 12:21PM  
12:14PM  
Aug-05-20 12:30AM  
Aug-04-20 09:15AM  
07:00AM  
Jul-30-20 04:01PM  
Jul-29-20 04:01PM  
Jul-16-20 03:27PM  
Jul-09-20 08:09AM  
Jul-05-20 03:05PM  
Jun-30-20 08:00AM  
Jun-22-20 08:30AM  
Jun-19-20 10:00AM  
May-27-20 04:30PM  
May-26-20 09:00AM  
May-14-20 04:15PM  
May-08-20 03:00PM  
May-07-20 04:01PM  
Apr-30-20 04:15PM  
Apr-29-20 08:47AM  
Apr-11-20 10:01AM  
Mar-16-20 09:15AM  
Mar-05-20 07:45AM  
06:30AM  
Feb-27-20 04:30PM  
Feb-26-20 12:30PM  
Feb-19-20 07:00AM  
Dec-17-19 07:03PM  
08:30AM  
Dec-10-19 12:12PM  
Nov-26-19 04:01PM  
Nov-21-19 09:00AM  
Nov-20-19 04:00PM  
Nov-17-19 08:00AM  
Nov-12-19 04:01PM  
Nov-07-19 06:02PM  
Nov-05-19 10:33AM  
Nov-01-19 08:00AM  
Oct-04-19 08:00AM  
08:00AM  
Sep-27-19 08:00AM  
Sep-26-19 08:15AM  
07:00AM  
Sep-17-19 04:01PM  
Sep-12-19 04:05PM  
Sep-11-19 01:34PM  
Aug-13-19 03:45PM  
Aug-12-19 10:23PM  
05:25PM  
04:02PM  
02:30PM  
Aug-05-19 10:30AM  
Aug-01-19 04:30PM  
Jul-11-19 12:13PM  
Jun-20-19 08:00AM  
Jun-19-19 04:30PM  
May-22-19 10:42AM  
May-09-19 11:23AM  
08:55AM  
07:46AM  
07:00AM  
May-02-19 10:33AM  
Apr-27-19 09:01AM  
Apr-25-19 07:00AM  
Mar-21-19 11:06AM  
Mar-06-19 12:22PM  
07:00AM  
Feb-27-19 07:00AM  
Feb-19-19 07:00AM  
Feb-15-19 07:00AM  
Feb-04-19 12:46PM  
07:00AM  
Dec-25-18 10:28AM  
Dec-13-18 07:56AM  
Dec-11-18 07:50AM  
07:00AM  
Dec-10-18 07:00AM  
Dec-05-18 04:30PM  
Nov-26-18 05:29PM  
Nov-13-18 10:15AM  
09:11AM  
07:00AM  
Oct-31-18 04:30PM  
Oct-22-18 08:10AM  
Oct-03-18 07:00AM  
Sep-24-18 04:30PM  
Aug-14-18 08:28PM  
12:48PM  
12:40PM  
07:26AM  
07:00AM  
06:00AM  
Aug-07-18 05:00PM  
Jul-02-18 05:11PM  
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It is also developing XHANCE, which is in Phase IIIb clinical trial for the treatment of chronic sinusitis; and OPN-300 for the treatment of Prader-Willi syndrome, a rare genetic obesity disorder, as well as autism spectrum disorder. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail (sumatriptan nasal powder) to treat migraine in adults; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2010 and is headquartered in Yardley, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Goldan Keith A.Chief Financial OfficerSep 23Buy3.902,5009,7439,751Sep 23 04:47 PM
Marino Michael F IIIChief Legal Officer & Corp SecSep 04Buy4.251,0004,25017,570Sep 09 02:53 PM
Marino Michael F IIIChief Legal Officer & Corp SecSep 01Buy4.301,0004,30016,570Sep 09 02:53 PM
Marino Michael F IIIChief Legal Officer & Corp SecAug 21Buy5.031,0005,03015,570Aug 25 02:00 PM
Marino Michael F IIIChief Legal Officer & Corp SecAug 20Buy5.251,0005,25014,570Aug 25 02:00 PM
Marino Michael F IIIChief Legal Officer & Corp SecAug 18Buy5.105002,55013,003Aug 18 06:49 PM
Marino Michael F IIIChief Legal Officer & Corp SecAug 17Buy5.212,00010,41012,503Aug 18 06:49 PM
Marino Michael F IIIChief Legal Officer & Corp SecAug 14Buy5.103,56718,20113,570Aug 18 06:49 PM
Mahmoud Ramy APresident and COOAug 11Option Exercise1.634,8617,9235,567Aug 12 07:27 PM
Mahmoud Ramy APresident and COOAug 11Option Exercise1.6314,54923,71572,268Aug 12 07:27 PM
Miller Peter KChief Executive OfficerAug 11Option Exercise1.637,42512,1038,500Aug 12 07:26 PM
Miller Peter KChief Executive OfficerAug 11Option Exercise1.6311,98819,540146,227Aug 12 07:26 PM
Miller Peter KChief Executive OfficerAug 11Sale7.002,56217,9445,938Aug 12 07:26 PM
Miller Peter KChief Executive OfficerAug 11Sale7.004,13828,983142,089Aug 12 07:26 PM
Mahmoud Ramy APresident and COOAug 11Sale7.001,67811,7533,889Aug 12 07:27 PM
Mahmoud Ramy APresident and COOAug 11Sale7.005,02235,17467,246Aug 12 07:27 PM
Mahmoud Ramy APresident and COOAug 10Option Exercise1.631,6822,7421,682Aug 12 07:27 PM
Mahmoud Ramy APresident and COOAug 10Option Exercise1.635,0228,18660,637Aug 12 07:27 PM
Miller Peter KChief Executive OfficerAug 10Option Exercise1.632,5624,1762,562Aug 12 07:26 PM
Miller Peter KChief Executive OfficerAug 10Option Exercise1.634,1406,748136,645Aug 12 07:26 PM
Miller Peter KChief Executive OfficerAug 10Sale7.008846,1881,678Aug 12 07:26 PM
Miller Peter KChief Executive OfficerAug 10Sale7.001,42910,003135,216Aug 12 07:26 PM
Mahmoud Ramy APresident and COOAug 10Sale7.005804,0601,102Aug 12 07:27 PM
Mahmoud Ramy APresident and COOAug 10Sale7.001,73312,13158,904Aug 12 07:27 PM
O'Neil Robert PDirectorMar 09Buy5.325,00026,5967,000Mar 09 04:33 PM
Scodari Joseph CDirectorMar 06Buy5.708,70049,60521,230Mar 09 07:07 AM
Scodari Joseph CDirectorDec 06Buy8.226,10050,14212,530Dec 09 02:42 PM
Avista Capital Partners II GP,10% OwnerNov 25Sale9.171,250,00011,456,250807,995Nov 26 05:41 PM
Venkataraman SriramDirectorNov 25Sale9.171,250,00011,456,250807,995Nov 26 05:36 PM